Direct Testing for KPC-Mediated Carbapenem Resistance from Blood Samples Using a T2 Magnetic Resonance Based Assay

• Main Authors: Giulia De Angelis (Author), Riccardo Paggi (Author), Thomas J. Lowery (Author), Jessica L. Snyder (Author), Giulia Menchinelli (Author), Maurizio Sanguinetti (Author), Brunella Posteraro (Author), Antonella Mencacci (Author)
• Format: Book
• Published: MDPI AG, 2021-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Molecular-based carbapenem resistance testing in Gram-negative bacterial bloodstream infections (BSIs) is currently limited because of the reliance on positive blood culture (BC) samples. The T2Resistance™ panel may now allow the detection of carbapenemase- and other β-lactamase encoding genes directly from blood samples. We detected carbapenem resistance genes in 11 (84.6%) of 13 samples from patients with BC-documented BSIs (10 caused by KPC-producing <i>Klebsiella</i><i>pneumoniae</i> and 1 caused by VIM/CMY-producing <i>Citrobacter freundii</i>). Two samples that tested negative for carbapenem resistance genes were from patients with BC-documented BSIs caused by KPC-producing <i>K. pneumoniae</i> who were receiving effective antibiotic therapy. In conclusion, our findings suggest that the T2Resistance™ panel can be a reliable tool for diagnosing carbapenem-resistant Gram-negative bacterial BSIs.

Item Description

10.3390/antibiotics10080950
2079-6382